PFE News and Press, Pfizer Inc. From 06/26/24

2024-06-26 10:06:00 ET When one player stumbles in a high-stakes competition, it's often to the glee of the other contenders. In mid-June, Pfizer 's (NYSE: PFE) gene-therapy candidate to treat Duchenne muscular dystrophy (DMD) didn't hit the mark in a late-stage clinical trial; it'd...

2024-06-25 12:54:41 ET Summary AstraZeneca is becoming a leader in the cancer therapeutics market, which is reflected in the growth of its share price. On June 25, 2024, Tagrisso, in combination with chemotherapy, was approved in Japan as the first-line treatment for people with N...

2024-06-25 12:31:58 ET More on CSL CSL Seqirus to provide more than 40M bird flu vaccine doses to Europe Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant Rating on CSL Historical earnings data for CSL Divi...

2024-06-25 12:14:00 ET Summary Pfizer CEO announced testing of three new weight loss drugs, one with a different mechanism than current GLP-1 agonists. Consumer confidence slightly down in May, with expectations index falling. Tesla recalls thousands of Cybertrucks over wiper ...

2024-06-25 09:45:00 ET It's obvious why Pfizer (NYSE: PFE) is eager to produce a medicine like Wegovy, Novo Nordisk 's (NYSE: NVO) smash-hit obesity therapy that's essentially a slightly different version of its type 2 diabetes drug called Ozempic. With such a gargantuan mar...

2024-06-25 09:00:00 ET Summary Catalent stock rose 3% after Elevidys label expansion approval by the FDA. Sarepta's stock reached an all-time high after Elevidys label expansion approval. Several companies including PFE, CAPR, RGNX, SLDB, VRTX, have DMD gene-therapy product candid...

2024-06-25 06:45:00 ET Summary Alnylam has been extremely persistent over the years in getting their RNA interference ideas developed and tested. That original RNAi therapy (patisiran) was directed towards neuropathy, but Alnylam has been hoping that such treatments would show ben...

2024-06-25 06:18:33 ET More on Pfizer Pfizer: Seriously Undervalued At Peak Pessimism Pfizer Stock: The Reversal Should Keep Going Pfizer: Headwinds Dissipating, New Obesity Pipeline Update Coming Soon Lilly, Novo Nordisk to dominate weight loss therapy marke...

2024-06-24 11:37:31 ET Summary HELIOS-B Phase III study of Amvuttra in patients with ATTR-CM succeeded across all metrics, showing significant benefits in both the combined study population and monotherapy groups. Amvuttra showed strong efficacy in reducing all-cause mortality and...

2024-06-23 14:00:00 ET More on Eli Lilly, Novo Nordisk Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity SA Asks: Who will launch the next big weight-loss drug? SA Asks: Is Eli Lilly or Novo No...